Exercise or conversion
Melissa B. Epperly
Director
Common Shares
- Value context
- $79.17K
- Reported price
- $4.46 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
Roivant Sciences Ltd.
Last 30 daysNo qualifying insider buying. Sales: $9.16M by 3 insiders.
Showing the first 6 of 20 trades on this page.
Director
Common Shares
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
CEO
Common Shares
President and Vant Chair
Common Shares
President & CIO
Common Shares
President & Immunovant CEO
Common Shares
President & Immunovant CEO
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
Chief Accounting Officer
Common Shares
CFO
Common Shares
Director
Common Shares
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Shares
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Shares
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Shares
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Shares
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Shares
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Director | Common SharesOption exercise or conversion10b5-1 | 17,750$4.46 / share | $79.17K | Oct 1Filed Oct 5 · 4d later | SEC filing |
| Director | Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units17,750$4.46 exercise / conversion price | Not a separate purchase | Oct 1Filed Oct 5 · 4d later | SEC filing |
| CEO | Common SharesExercise-price or tax withholding | 76,171$36.57 / share | $2.79M | Sep 30Filed Oct 2 · 2d later | SEC filing |
| President and Vant Chair | Common SharesExercise-price or tax withholding | 40,309$36.57 / share | $1.47M | Sep 30Filed Oct 2 · 2d later | SEC filing |
| President & CIO | Common SharesExercise-price or tax withholding | 46,879$36.57 / share | $1.71M | Sep 30Filed Oct 2 · 2d later | SEC filing |
| President & Immunovant CEO | Common SharesOption exercise or conversion10b5-1 | 200,000$3.85 / share | $770K | Sep 30Filed Oct 2 · 2d later | SEC filing |
| President & Immunovant CEO | Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units200,000$3.85 exercise / conversion price | Not a separate purchase | Sep 30Filed Oct 2 · 2d later | SEC filing |
| Chief Accounting Officer | Common SharesExercise-price or tax withholding | 3,880$39.77 / share | $154.31K | Sep 20Filed Sep 22 · 2d later | SEC filing |
| CFO | Common SharesExercise-price or tax withholding | 2,129$39.77 / share | $84.67K | Sep 20Filed Sep 22 · 2d later | SEC filing |
| Director | Common SharesGrant or award | 5,054Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units10,531Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
| Director | Common SharesGrant or award | 5,054Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units10,531Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
| Director | Common SharesGrant or award | 5,054Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units10,531Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
| Director | Common SharesGrant or award | 5,054Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units10,531Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
| Director | Common SharesGrant or award | 5,054Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units10,531Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
| Director | Common SharesGrant or award | 5,054Award · no purchase price | Non-cash award | Sep 16Filed Sep 18 · 2d later | SEC filing |
Showing the latest 20 of 91 trades. Show all 91 trades
Roivant Sciences Ltd. - Common Shares (ROIV) · Stock
The filing reports a sale for a spouse.
Lisa McClainReporting House memberRoivant Sciences Ltd. - Common Shares (ROIV) · Stock
The filing reports a purchase for a spouse.
Lisa McClainReporting House memberRoivant Sciences Ltd. - Common Shares (ROIV) · Stock
The filing reports a sale for a spouse.
Lisa McClainReporting House memberNo eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.